BB Biotech

Daniel Koller, BB Biotech's head of investment, discusses sector growth, innovation and the attractive valuations of fast-growing companies.

Equity markets performed well in the first quarter driven by an expectation of lower corporate tax rates in the US and the potential repatriation of offshore cash and investments in infrastructure.

New products, strong finances and robust growth were the main talking points at JP Morgan's recent healthcare conference in San Francisco. There were positive signals regarding the fundraising climate, as well as the strength of innovation within the...

Biotech investments

Set to start trading on Friday 2 December

Rallied following Clinton defeat

JPMorgan trusts leading the winners

The biotechnology sector has been hit particularly hard by the risk-averse sentiment sweeping through global stock markets and after reaching a high in July 2015, the Nasdaq Biotechnology index shed about one-third of its value.